Loading clinical trials...
Loading clinical trials...
realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients
Conditions
Interventions
Tafasitamab
Locations
25
United States
Alabama Oncology
Birmingham, Alabama, United States
Clearview Cancer Institute
Huntsville, Alabama, United States
University of California, Irvine Medical Center
Orange, California, United States
McFarland Clinic P.C.
Ames, Iowa, United States
Mission Cancer and Blood
Des Moines, Iowa, United States
Tulane Cancer Center
New Orleans, Louisiana, United States
Start Date
September 20, 2021
Primary Completion Date
October 31, 2025
Completion Date
August 31, 2026
Last Updated
December 10, 2024
NCT05139017
NCT01804686
NCT07443514
NCT05755087
NCT04739813
NCT06785818
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions